drugset
drugset / Trial / NCT03355612

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

NCT03355612 ↗

Phase 3 Unknown 456 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, multicenter, controlled study to compared the Efficacy and Safety of XELOX combined with Apatinib versus XELOX as post-operative chemotherapy in locally advanced gastric signet ring carcinoma with D2 dissection.

Timeline

Start
2017-12-20
Primary completion
2020-12-20
Completion
2025-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg Oral
Background Capecitabine Small molecule 1000 mg/m2 —
Background Oxaliplatin Small molecule 130 mg/m2 —

Indications

gastric carcinoma